H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024.
H.R. 4366 - Consolidated Appropriations Act of 2024.
H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act.
Issues pertaining to NIH appropriations for FY25.
Legislative outreach and monitoring related to insulin affordability.
S. 1269 - INSULIN Act of 2023.
S.1855 - Special Diabetes Program Reauthorization Act of 2023.
Duration: January 1, 2008
to
present
General Issues: Budget/Appropriations , Health Issues , Taxation/Internal Revenue Code , Small Business , Economics/Economic Development , Medicare/Medicaid , Insurance , Medical/Disease Research/Clinical Labs , Postal , Veterans
Spending: about $10,905,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: U.S. Senate, House of Representatives, U.S. Senate,, Health & Human Services - Dept of (HHS), Defense - Dept of (DOD), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS),
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 22.
Original Filing: 301575982.xml
Lobbying Issues
H.R. 2872 - Further Additional Continuing Appropriations and Other Extensions Act, 2024.
H.R. 4366 - Consolidated Appropriations Act of 2024.
H.R. 7463 - the Extension of Continuing Appropriations and Other Matters Act.
Issues pertaining to NIH appropriations for FY25.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislative outreach and monitoring related to insulin affordability.
S. 1269 - INSULIN Act of 2023.
S.1855 - Special Diabetes Program Reauthorization Act of 2023.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2023
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 22.
Original Filing: 301536060.xml
Lobbying Issues
H.R. 6363 - Further Continuing Appropriations and Other Extensions Act, 2024.
Advocacy for inclusion of Special Diabetes Program funding.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Legislative outreach and monitoring related to insulin affordability.
H.R. 5378 - Lower Costs, More Transparency Act.
S. 1269 - INSULIN Act of 2023.
S.1855 - Special Diabetes Program Reauthorization Act of 2023.
S.2205/H.R. 4304 - The ISLET Act.
S. 1832 / H.R. 3842 - Expanding Access to Diabetes Self-Management Training Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 566/H.R. 3435 - Charitable Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 20, 2023.
Original Filing: 301515942.xml
Lobbying Issues
S. 2624/H.R. 5894 - Makingappropriationsfor the Departments of Labor,Healthand Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes.
H.R. 4368 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
H.R. 5860 - Continuing Appropriations Act, 2024 and Other Extensions Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 4420 - Preparedness and Response Reauthorization Act
H.R. 3561 - PATIENT Act of 2023
H.R. 5378 - Lower Costs, More Transparency Act
S.1855 - Special Diabetes Program Reauthorization Act of 2023
S. 1269 - INSULIN Act of 2023
S. 954/H.R. 1488 - Affordable Insulin Now Act
H.R. 4758/S. 2372 - Accelerating Kids Access to Care Act
S.2205/H.R. 4304 - The ISLET Act
Issues related to Medicare and Medicaid
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2023
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 20, 2023.
Original Filing: 301490074.xml
Lobbying Issues
Issues related to NIH & ARPA-H Funding
S. 2131/H.R. 4368 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2547 - Special Diabetes Program for Indians Reauthorization Act of 2023
H.R. 2550 - Special Diabetes Program Reauthorization Act of 2023
S. 1855 - Special Diabetes Program Reauthorization Act of 2023
S. 1269 - INSULIN Act of 2023
H.R. 1488 - Affordable Insulin Now Act
S. 954 - Affordable Insulin Now Act
H.R. 3561 - PATIENT Act of 2023
Issues related to insulin affordability
Issues related to collection of race and ethnicity data
Issues related to Medicare and Medicaid
Issues related to preventative care
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2023
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 20, 2023.
Original Filing: 301466706.xml
Lobbying Issues
Issues related to funding for the National Institutes of Health and the U.S. Food and Drug Administration
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, particularly as it relates to insulin
S. 146 - Cap Insulin Prices Act
HR 1488/S. 954 - Affordable Insulin Now Act
H.R. 1485 - Insulin for All Act of 2023
H.R.1587 - Making Insulin Affordable for All Children Act
Issues related to the Special Diabetes Program renewal
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2022
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 20, 2023.
Original Filing: 301439654.xml
Lobbying Issues
H.R. 2617, the Consolidated Appropriations Act, 2023
Issues related to HHS/NIH/FDA funding
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, particularly as it relates to insulin
S. 4446, Modernizing the Accelerated Approval Pathway Act of 2022
H.R. 6963, Accelerated Approval Integrity Act of 2022
H.R. 4128/S. 2209, VALID Act of 2021
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 4808, Enhancing American Retirement (EARN) Act
S. 243, Legacy IRA Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 20, 2022.
Original Filing: 301418134.xml
Lobbying Issues
H.R. 5376 - Inflation Reduction Act of 2022
H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
H.R. 6833 - Making continuing appropriations for Fiscal Year 2023, and for other purposes
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, particularly as it relates to insulin
Issues related to coverage of preventive services
Issues related to clinical trial diversity
H.R.6963 - Accelerated Approval Integrity Act of 2022
S. 4446 - The Modernizing the Accelerated Approval Pathway Act of 2022
H.R. 3089/ S. 1544 - The Accelerating Kids Access to Care Act (AKACA)
H.R. 6833/ S. 3700 - Affordable Insulin Now Act
H.R. 7667 - Food and Drug Amendments of 2022
S. 4348 - FDASLA Act of 2022
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2954 - Securing A Strong Retirement Act
Issues pertaining to charitable contributions
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 20, 2022.
Original Filing: 301390871.xml
Lobbying Issues
H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Issues pertaining to budget reconciliation
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 5585 - Advanced Research Projects Agency - Health
H.R. 6000 - Cures 2.0 Act
H.R. 6833 - Affordable Insulin Now Act
H.R. 6963 - Accelerated Approval Integrity Act of 2022
H.R. 7667 - Food and Drug Amendments of 2022
Issues related to prescription drug pricing, particularly as it relates to insulin
S. 3700 - Affordable Insulin Now Act
S. 3819 - ARPA-H Act
S. 4348 - FDASLA Act of 2022
S. 4446 - The Modernizing the Accelerated Approval Pathway Act of 2022
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2954 - Securing A Strong Retirement Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2022
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 20, 2022.
Original Filing: 301370043.xml
Lobbying Issues
H.R.5376 - Build Back Better Act
Labor-HHS Appropriations
Agriculture-FDA Appropriations
H.R. 6617-Further Additional Extending Government Funding Act
H.R. 2471- the Consolidated Appropriations Act,2022
Issues related to HHS/NIH/FDA funding
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, particularly as it relates to insulin
Issues related to the FDA Accelerated Approval Program
H.R. 19 - Lower Costs, More Cures Act of 2021
H.R. 6000 - Cures 2.0 Act
H.R. 5585 - Advanced Research Projects Agency - Health
H.R. 6833 - Affordable Insulin Now Act
S. 3700 - Affordable Insulin Now Act
S. 3819 - ARPA-H Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2954 - Securing A Strong Retirement Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2021
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 20, 2022.
Original Filing: 301337016.xml
Lobbying Issues
H.R. 5376 - Build Back BetterAct
H.R. 6119 - Further Extending Government Funding Act
Labor-HHS Appropriations
Agriculture-FDA Appropriations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, particularly as it relates to insulin
H.R. 6000 - Cures 2.0 Act
H.R. 5585 - Advanced Research Projects Agency - Health
H.R. 5030/S.2706 - DIVERSE Trials Act
Issues related to FDA Leadership
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1704/S.618 - Universal Giving Pandemic Response and Recovery Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2021
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 20, 2021.
Original Filing: 301308406.xml
Lobbying Issues
Issues related to budget reconciliation
H.R. 4502 - Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
H.R. 4356/S. 2599 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 289/H.R. 869 - RISE Act of 2021
Issues related to prescription drug pricing, particularly as it relates to insulin
Issues and legislation related to providing (during the COVID-19 emergency period) and preserving (post the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes
Issues related to the creation of the Advanced Research Projects Agency for Health (ARPA-H)
H.R. 3437 Long-term Opportunities for Advancing New Studies (LOANS) for Biomedical Research Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 243 Legacy IRA Act
Issues related to expanding tax exclusion for IRA distributions for charitable purposes
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2021
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 20, 2021.
Original Filing: 301288956.xml
Lobbying Issues
Issues related to appropriations for HHS, NIH, FDA, and CDC
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 289/H.R. 869 - RISE Act of 2021
Issues related to drug pricing, particularly as it relates to insulin
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions
Issues and legislation related to providing (during the COVID-19 emergency period) and preserving (post the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes
Issues related to surprise medical billing
H.R. 3437 Long-term Opportunities for Advancing New Studies (LOANS) for Biomedical Research Act
S. 2164/H.R. 19 - Lower Costs, More Cures Act of 2021
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 740 - WORK NOW Act
Issues related to financial relief and nonprofit assistance in response to the COVID-19 pandemic
S. 243 Legacy IRA Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2021
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 20, 2021.
Original Filing: 301265646.xml
Lobbying Issues
Issues related to appropriations for NIH, FDA and CDC
H.R. 1319 - American Rescue Plan Act of 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 289/H.R. 869 - RISE Act of 2021
S. 799 - Protecting Americans with Pre-Existing Conditions Act of 2021
Issues related to drug pricing, particularly as it relates to insulin
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions
Issues and legislation related to providing (during the COVID-19 emergency period) and preserving (post the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 618 - Universal Giving Pandemic Response and Recovery Act
S. 740 - WORK NOW Act
Issues related to financial relief and nonprofit assistance in response to the COVID-19 pandemic
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2020
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 21, 2021.
Original Filing: 301244513.xml
Lobbying Issues
H.R. 8337 - FY2021 Continuing Appropriations Resolution (P.L. 116-159)
H.R. 133 - Consolidated Appropriations Act, 2021
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1895 - Lower Health Care Costs Act
H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019
H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019
S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020
H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act)
S. 2543 - The Prescription Drug Pricing Reduction Act of 2019
S. 2199, H.R. 4906 - Insulin Price Reduction Act
S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019
H.R. 3 - Lower Drug Costs Now Act of 2019
H.R. 5749 - Affordable Insulin for All Act
S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act
H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019
Issues and legislation related to drug pricing, specifically as it relates to insulin.
Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D.
Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs.
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.
Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes.
S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act
H.R. 3630 - No Surprises Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1948, H.R. 3709 -- Chronic Disease Management Act of 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. 3814 - RESTART Act
H.R. 6892 - To amend the CARES Act to add requirements for the Main Street Lending Program related to non-profit organizations, small businesses, minority depository institutions, and community development financial institutions, and for other purposes.
Issues related to financial relief packages and nonprofit assistance in response to the COVID-19 pandemic.
S. 4032/ H.R. 7324 - Universal Giving Pandemic Response Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2020
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 20, 2020.
Original Filing: 301221548.xml
Lobbying Issues
H.R. 7610, H.Rept. 116-446 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations
H.R. 7614, H. Rept. 116-450 - Labor, Health and Human Services, and Education, and Related Agencies Appropriations
H.R. 8337 - FY2021 Continuing Appropriations Resolution
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1895 - Lower Health Care Costs Act
H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019
H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019
S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020
H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act)
S. 2543 - The Prescription Drug Pricing Reduction Act of 2019
S. 2199, H.R. 4906 - Insulin Price Reduction Act
S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019
H.R. 3 - Lower Drug Costs Now Act of 2019
H.R. 5749 - Affordable Insulin for All Act
S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act
H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019
Issues and legislation related to drug pricing, specifically as it relates to insulin.
Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D.
Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs.
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.
H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019
Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes.
S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1948, H.R. 3709 -- Chronic Disease Management Act of 2019
Issues in the House of Representatives related to amending the Internal Revenue Code, with respect to health savings accounts (HSAs), to allow the high deductible health plans required for an HSA to provide care for chronic conditions with no deductible - discussions outside the scope of S. 1948 and H.R. 3709.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6800 - Health and Economic Recovery Omnibus Emergency Solutions Act or the HEROES Act
S. 3814 - RESTART Act
H.R. 6892 - To amend the CARES Act to add requirements for the Main Street Lending Program related to non-profit organizations, small businesses, minority depository institutions, and community development financial institutions, and for other purposes.
Issues related to financial relief packages and nonprofit assistance in response to the COVID-19 pandemic.
S. 4032/ H.R. 7324 - Universal Giving Pandemic Response Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 20, 2020.
Original Filing: 301201253.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration,and Related Agencies Appropriations
Labor, Health and Human Services, and Education,and Related Agencies Appropriations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1895 - Lower Health Care Costs Act
H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019
H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019
S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020
H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act)
S. 2543 - The Prescription Drug Pricing Reduction Act of 2019
S. 2199, H.R. 4906 - Insulin Price Reduction Act
S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019
H.R. 3 - Lower Drug Costs Now Act of 2019
H.R. 5749 - Affordable Insulin for All Act
S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act
H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019
Issues and legislation related to drug pricing, specifically as it relates to insulin.
Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D.
Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs.
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.
H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019
Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes.
Issues related to hospital inpatient blood glucose monitoring.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1948, H.R. 3709 -- Chronic Disease Management Act of 2019
Issues in the House of Representatives related to amending the Internal Revenue Code, with respect to health savings accounts (HSAs), to allow the high deductible health plans required for an HSA to provide care for chronic conditions with no deductible - discussions outside the scope of S. 1948 and H.R. 3709.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 6800 - Health and Economic Recovery Omnibus Emergency Solutions Act or the HEROES Act
S. 3814 - RESTART Act
H.R. 6892 - To amend the CARES Act to add requirements for the Main Street Lending Program related to non-profit organizations, small businesses, minority depository institutions, and community development financial institutions, and for other purposes.
Issues related to financial relief packages and nonprofit assistance in response to the COVID-19 pandemic.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 20, 2020.
Original Filing: 301176481.xml
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration,and Related Agencies Appropriations
Labor, Health and Human Services, and Education,and Related Agencies Appropriations
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1895 - Lower Health Care Costs Act
H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019
H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019
H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act)
H.R. 965 - CREATES Act of 2019
S. 2543 - The Prescription Drug Pricing Reduction Act of 2019
S. 2199, H.R. 4906 - Insulin Price Reduction Act
S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019
H.R. 3 - Lower Drug Costs Now Act of 2019
S. 2855 - Insulin Affordability Data Collection Act
H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019
Issues and legislation related to drug pricing, specifically as it relates to insulin
Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D.
Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.
H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019
Issues relates to expanding telehealth under Medicare for the purposes of qualifying visits for insulin pumps and continuous glucose monitors.
S. 3548, H.R. 748 - CARES Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1948, H.R. 3709 -- Chronic Disease Management Act of 2019
Issues in the House of Representatives related to amending the Internal Revenue Code, with respect to health savings accounts (HSAs), to allow the high deductible health plans required for an HSA to provide care for chronic conditions with no deductible - discussions outside the scope of S. 1948 and H.R. 3709.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S. 3548, H.R. 748 - CARES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2019
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 21, 2020.
Original Filing: 301126397.xml
Lobbying Issues
H.R. 1865, P.L. 116-94 - FY 2020 Further Consolidated Appropriations Act
H.R. 4378, H. Res. 564, P.L. 116-59 - FY 2020 Continuing Appropriations Resolution (through 11/21/19)
H.R. 3055, H. Res. 708, P.L. 116-69 - FY 2020 Continuing Appropriations Resolution (through 12/20/19)
H.R. 2740, H. Rept. 116-62 -- Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1895 - Lower Health Care Costs Act
H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019
H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019
H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act)
H.R. 965 - CREATES Act of 2019
S. 2543 - The Prescription Drug Pricing Reduction Act of 2019
S. 2199, H.R. 4906 - Insulin Price Reduction Act
S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019
H.R. 3 - Lower Drug Costs Now Act of 2019
S. 2855 - Insulin Affordability Data Collection Act
H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019
Issues and legislation related to drug pricing, specifically as it relates to insulin
Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.
H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1948, H.R. 3709 -- Chronic Disease Management Act of 2019
Issues in the House of Representatives related to amending the Internal Revenue Code, with respect to health savings accounts (HSAs), to allow the high deductible health plans required for an HSA to provide care for chronic conditions with no deductible - discussions outside the scope of S. 1948 and H.R. 3709.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 18, 2019.
Original Filing: 301071526.xml
Lobbying Issues
H.R. 3164, S. 2522, H. Rept. 116-107, S. Rept. 116-110 -- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
H.R. 2740, H. Rept. 116-62 -- Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020
H.R. 4378, H. Res. 564, P.L. 116-59 - FY 2020 Continuing Appropriations Resolution (through 11/21/19)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 192 - Community and Public Health Programs Extension Act
S. 1895 - Lower Health Care Costs Act
H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019
H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019
H.R. 965 - CREATES Act of 2019
Issues related to the proposed, Department of Health and Human Services (HHS), changes to the Anti-Kickback statutes safe harbors.
Issues and legislation related to drug pricing, specifically as it relates to Insulin.
S. 2004 -- Emergency Access to Insulin Act of 2019
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1948 -- Chronic Disease Management Act of 2019
Issues in the House of Representatives related to amending the Internal Revenue Code, with respect to health savings accounts (HSAs), to allow the high deductible health plans required for an HSA to provide care for chronic conditions with no deductible.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2019
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 19, 2019.
Original Filing: 301052356.xml
Lobbying Issues
H.R. 2740, H. Res. 431, H. Rept. 116-42 - Omnibus package which combines (1) Labor-HHS-Education (H.R. 2740), (2) Defense (H.R. 2968), (3) State-Foreign Operations (H.R. 2839, as modified by the first rule), and (4) Energy and Water (H.R. 2960).
H.R. 3055, H. Res 445, H. Rept. 116-101 - Omnibus package which combines (1) CJS (H.R. 3055), (2) Agriculture (H.R. 3164), (3) Interior (H.R. 3052), (4) Mil-Con, VA (H.R. 2745), and THUD (H.R. 3163).
H.R. 3164, H. Rept. 116-107 -- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
H.R. 2740, H. Rept. 116-62 -- Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020
H.R. 6147, H. Rept. 115-765, Interior, Environment, Financial Services and General Government, Agriculture, Rural Development, Food and Drug Administration, and Transportation, Housing and Urban Development Appropriations Act, 2019
As it relates to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020
As it relates to the Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 192 - Community and Public Health Programs Extension Act
S. 1895 - Lower Health Care Costs Act
H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019
H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019
H.R. 965 - CREATES Act of 2019
Issues related to the proposed, Department of Health and Human Services (HHS), changes to the Anti-Kickback statutes safe harbors.
Issues and legislation related to drug pricing, specifically as it relates to Insulin.
S. 2004 -- Emergency Access to Insulin Act of 2019
S. 1948 -- Chronic Disease Management Act of 2019
Issues in the House of Representatives related to amending the Internal Revenue Code, with respect to health savings accounts (HSAs), to allow the high deductible health plans required for an HSA to provide care for chronic conditions with no deductible.
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2019
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 19, 2019.
Original Filing: 301031071.xml
Lobbying Issues
H.J. Res 31, H. Rept. 116-9, P.L. 116-6 - Consolidated Appropriations Act of 2019
H.R. 648 - 2nd Consolidated Appropriations Act, 2019
H.R. 21 - Consolidated Appropriations Act
H.J. Res. 31 - FY 2019 Appropriations for Homeland Security through 2/28/2019
(Note: Becomes vehicle for Consolidated Appropriations Act 2019)
H.J. Res. 28, P.L. 116-5 - FY 2019 Further Additional Continuing Appropriation Act through 2/15/19
H.J. Res. 27 - FY 2019 Further Additional Continuing Appropriations Act through 2/15/19
Note: FY 2019 continuing appropriations resolution amending P.L. 115-245 to provide an extension of continuing appropriations through 2/1/19 for the remaining seven outstanding FY 2019 appropriations bills.
H.R. 268, S. Amdt. 5, S. Amdt. 6 - Making Supplemental Appropriations for FY 2019
H.R. 265 -- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
H.R. 5961, H. Rept. 115-706 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019
S. 2976, S. Rept. 115-259 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019
H.R. 6147, H. Rept. 115-765, Interior, Environment, Financial Services and General Government, Agriculture, Rural Development, Food and Drug Administration, and Transportation, Housing and Urban Development Appropriations Act, 2019
As it relates to the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020
As it relates to the Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 192 - Community and Public Health Programs Extension Act
Issues related to reauthorization, in the House of Representative, of the Special Diabetes Program (SDP) and the Special Diabetes Program for Indians (SDPI)
H.R. 107 -- To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single sourcedrugs and innovator multiple sourcedrugs.
H.R. 965 - CREATES Act of 2019
Issues related to the proposed, Department of Health and Human Services (HHS), changes to the Anti-Kickback statutes safe harbors.
Issues related to drug pricing, specifically as it relates to Insulin.
Issues related to amending the Internal Revenue Code, with respect to health savings accounts (HSAs), to allow the high deductible health plans required for an HSA to provide care for chronic conditions with no deductible.
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2018
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 20, 2019.
Original Filing: 301011377.xml
Lobbying Issues
H.R. 5961, H. Rept. 115-706 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019
S. 2976, S. Rept. 115-259 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019
H.R. 6147, H. Rept. 115-765, Interior, Environment, Financial Services and General Government, Agriculture, Rural Development, Food and Drug Administration, and Transportation, Housing and Urban Development Appropriations Act, 2019
H.R. 695, To provide continuing appropriations for, Agriculture; Commerce, Justice, Science; Financial Services and General Government; Homeland Security; Interior; State, Foreign Operations; and Transportation, Housing and Urban Development.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 6642 - To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Issues related to drug pricing, specifically as it relates to insulin.
Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions.
Issues related to reauthorization of the Special Diabetes Program (SDP)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2018
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 19, 2018.
Original Filing: 300990186.xml
Lobbying Issues
H.R. 5961, H. Rept. 115-706 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019
S. 2976, S. Rept. 115-259 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019
H.R. 6470, H. Rept. 115-862, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
S. 3158, S. Rept. 115-289, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 6642 - To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs.
Issues related to drug pricing, specifically as it relates to insulin.
Issues related to importance of preserving health insurance protections for pre-existing conditions.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2018
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 19, 2018.
Original Filing: 300970183.xml
Lobbying Issues
H.R. 3268, H. Rept. 115-232 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
S. 1603, S. Rept. 115-131 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
H.R. 3358, H. Rept. 115-244, Labor, Health and Human Services, Education and Related Agencies Appropriations Act, FY 2018
S. 1771, S. Rept. 115-150, Labor, Health and Human Services, Education and Related Agencies Appropriations Act, FY 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the use of smart technology in collaboration with devices for the management
of type 1 diabetes (T1D).
Issues related to drug pricing, specifically as it relates to Insulin.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2018
JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) amended a lobbying report for in-house lobbying in Q12018 on Sept. 12, 2018
Original Filing: 300981663.xml
Lobbying Issues
H.R. 3268, H. Rept. 115-232 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
S. 1603, S. Rept. 115-131 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 920 - National Clinical Care Commission Act
H.R. 3917 - To amend the Public Health Service Act to extend funding for the Special Diabetes Program for Indians
H.R. 3924 - To amend the Public Health Service Act to extend funding for the Special Diabetes Program for Type 1 Diabetes
H.R. 4541 - CHAMPION KIDS Act of 2017
H.R. 3922, H. Rept. 115-359 - CHAMPIONING HEALTHY KIDS Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2018
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 18, 2018.
Original Filing: 300946769.xml
Lobbying Issues
H.R. 3268, H. Rept. 115-232 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
S. 1603, S. Rept. 115-131 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
H.R. 3358, H. Rept. 115-244, Labor, Health and Human Services, Education and Related Agencies Appropriations Act, FY 2018
S. 1771, S. Rept. 115-150, Labor, Health and Human Services, Education and Related Agencies Appropriations Act, FY 2018
H.R. 1625, H.R. 3354, H.R. 3219, H. Res. 500, P.L. 115-141, Vehicle for Consolidated Appropriations Act of 2018
H.R. 1892, P.L. 115-123, Continuing Resolution through March 23, 2018 - Includes language to reauthorize the Special Diabetes Program
H.R. 195, P.L. 115-120, Continuing Resolution through February 8, 2018
H.R. 1370, P.L. 115-96, Continuing Resolution through January 19, 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 3917 - To amend the Public Health Service Act to extend funding for the Special Diabetes Program for Indians
H.R. 3924 - To amend the Public Health Service Act to extend funding for the Special Diabetes Program for Type 1 Diabetes
H.R. 4541 - CHAMPION KIDS Act of 2017
H.R. 3922, H. Rept. 115-359 - CHAMPIONING HEALTHY KIDS Act
Issues related to the use of smart technology in collaboration with devices for the management
of type 1 diabetes (T1D).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2017
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 11, 2018.
Original Filing: 300922774.xml
Lobbying Issues
H.R. 3268, H. Rept. 115-232 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
S. 1603, S. Rept. 115-131 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 920 - National Clinical Care Commission Act
H.R. 3917 - To amend the Public Health Service Act to extend funding for the Special Diabetes Program for Indians
H.R. 3924 - To amend the Public Health Service Act to extend funding for the Special Diabetes Program for Type 1 Diabetes
H.R. 4541 - CHAMPION KIDS Act of 2017
H.R. 3922, H. Rept. 115-359 - CHAMPIONING HEALTHY KIDS Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2017
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 18, 2017.
Original Filing: 300906368.xml
Lobbying Issues
H.R. 3268 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
S. 1603-- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2018
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 920 - National Clinical Care Commission Act
H.R. 2430, H. Rept. 115-201, P.L. 115-52 - FDA Reauthorization Act of 2017
H.R. 1628, H. Rept. 115-52 - American Health Care Act of 2017
H.R. 1628, An Amendment in the Nature of a Substitute [LYN17744] (Graham/Cassidy)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2017
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 19, 2017.
Original Filing: 300889102.xml
Lobbying Issues
H.R. 5054, S. 2956 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2017
H.R. 5926, S. 3040 - Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, FY 2017
H.R. 2028 - Further Continuing and Security Assistance Appropriations Act
H.J.Res. 99 - Making Further Continuing Appropriations for FY2017 and for other purposes
H.R. 244 - Consolidated Appropriations Act of 2017 - Specifically Divisions A & H
FY 2018 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
FY 2018 Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 309 - National Clinical Care Commission Act
Issues related to reauthorization of the Food and Drug Administration User Fee Programs
H.R. 1628, H. Rept. 115-52 - American Health Care Act of 2017, Better Care Reconciliation Act of 2017
H. Res. 228 -- Providing for consideration of the bill (H.R. 1628) to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2017
JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) amended a lobbying report for in-house lobbying in Q12017 on April 20, 2017
Original Filing: 300876658.xml
Lobbying Issues
H.R. 5054 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2017
S. 2956 -- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2017
S. 3040 - Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, FY 2017
H.R. 5926 -- S. 3040 - Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, FY 2017
H.R. 2028 - Further Continuing and Security Assistance Appropriations Act
FY 2018 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 309 - National Clinical Care Commission Act
Issues related to reauthorization of the Food and Drug Administration User Fee Programs
H.R. 1628, H. Rept. 115-52 - American Health Care Act of 2017
H. Res. 228 -- Providing for consideration of the bill (H.R. 1628) to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2017
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 20, 2017.
Original Filing: 300875951.xml
Lobbying Issues
H.R. 5054 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2017
S. 2956 -- Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY 2017
S. 3040 - Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, FY 2017
H.R. 5926 -- S. 3040 - Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, FY 2017
H.R. 2028 - Further Continuing and Security Assistance Appropriations Act
FY 2018 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 309 - National Clinical Care Commission Act
Issues related to reauthorization of the Food and Drug Administration User Fee Programs
H.R. 1628, H. Rept. 115-52 - American Health Care Act of 2017
H. Res. 228 -- Providing for consideration of the bill (H.R. 1628) to provide for reconciliation pursuant to title II of the concurrent resolution on the budget for fiscal year 2017.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2016
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 23, 2017.
Original Filing: 300856456.xml
Lobbying Issues
H.R. 5054 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017
S. 2956 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017
S. 3040 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017
H.R. 5926 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017
H.R. 5325 - Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act, 2017, and Zika Response and Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1427/S. 804 - Medicare CGM Access Act of 2015
H.R. 6 - 21st Century Cures Act
S. 2700 - FDA and NIH Workforce Authorities Modernization Act
H.R. 1192/S. 586 - National Diabetes Clinical Care Commission Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2016
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 20, 2016.
Original Filing: 300836434.xml
Lobbying Issues
H.R. 5054 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017
S. 2956 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017
S. 3040 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017
H.R. 5538 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017
H.R. 5325 - Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriation Act, 2017, and Zika Response and Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1427/S. 804 - Medicare CGM Access Act of 2015
H.R. 6 - 21st Century Cures Act
S. 2700 - FDA and NIH Workforce Authorities Modernization Act
H.R. 1192/S. 586 - National Diabetes Clinical Care Commission Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2016
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 19, 2016.
Original Filing: 300813453.xml
Lobbying Issues
H.R. 5054 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017
S. 2956 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017
S. 3040 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017
H.R. - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1427/S. 804 - Medicare CGM Access Act of 2015
H.R. 6 - 21st Century Cures Act
S. 2700 - FDA and NIH Workforce Authorities Modernization Act
S. 2689/H.R. 4762 - Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2016
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 19, 2016.
Original Filing: 300795177.xml
Lobbying Issues
FY17 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act
FY17 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1427/S. 804 - Medicare CGM Access Act of 2015
H.R. 1192/S. 586 - National Diabetes Clinical Care Commission Act
H.R. 6 - 21st Century Cures Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2015
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 13, 2016.
Original Filing: 300770982.xml
Lobbying Issues
H.R. 3049/S. 1800 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016
H.R. 3020/S. 1695 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
H.R. 2029 - Consolidated Appropriations Act, 2016
S. 2129 - An Act Making Appropriations to Improve the Nation's Infrastructure and for Other Purposes, 2016
S. 2132 - An Act Making Appropriations to Stop Regulatory Excess and for Other Purposes, 2016
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1427/S. 804 - Medicare CGM Access Act of 2015
H.R. 1192/S. 586 - National Diabetes Clinical Care Commission Act
H.R. 6 - 21st Century Cures Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2015
JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) amended a lobbying report for in-house lobbying in Q32015 on July 14, 2016
Original Filing: 300809416.xml
Lobbying Issues
H.R. 3049/S. 1800 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016
H.R. 3020/S.1695 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
H.R. 719 - Continuing Appropriations Act, 2016
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1427/S. 804 Medicare CGM Access Act of 2015
H.R. 1192/S. 586 National Diabetes Clinical Care Commission Act
H.R. 6 21st Century Cures Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2015
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 16, 2015.
Original Filing: 300755405.xml
Lobbying Issues
H.R. 3049/S. 1800 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016
H.R. 3020/S.1695 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
H.R. 719 - Continuing Appropriations Act, 2016
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1427/S. 804 Medicare CGM Access Act of 2015
H.R. 1192/S. 586 National Diabetes Clinical Care Commission Act
H.R. 6 21st Century Cures Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2015
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 20, 2015.
Original Filing: 300743486.xml
Lobbying Issues
S. Con. Res. 11 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.
H.R. 3049 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016
H.R. 3020/S.1695 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2016
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1427/S. 804 Medicare CGM Access Act of 2015
H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015
H.R. 1192/S. 586 National Diabetes Clinical Care Commission Act
H.R. 6 21st Century Cures Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2015
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 20, 2015.
Original Filing: 300724740.xml
Lobbying Issues
H.R. 1427/S. 804 Medicare CGM Access Act
H.R. 2 Medicare Access and CHIP Reauthorization Act of 2015
H.R. 1192/S. 586 National Diabetes Clinical Care Commission Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.Con.Res.27 - Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025.
S. Con.Res.11 - An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2014
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 16, 2015.
Original Filing: 300698866.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1428 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
S. 945/H.R. 1274 - Access to Quality Diabetes Education Act of 2013
S. 2689/H.R. 5644 - Medicare CGM Access Act of 2014
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 83 - FY 2015 Omnibus; Consolidated and Further Continuing Appropriations Act
H.J. Res. 131 - Making further continuing appropriations for fiscal year 2015, and for other purposes
H.J. Res. 130 - FY 2015 Continuing Resolution
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) amended a lobbying report for in-house lobbying in Q32014 on July 14, 2016
Original Filing: 300809419.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1428 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
S. 945/H.R. 1274 - Access to Quality Diabetes Education Act of 2013
S. 2689/H.R. 5644 - Medicare CGM Access Act of 2014
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2014
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 17, 2014.
Original Filing: 300679032.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1428 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
S. 945/H.R. 1274 - Access to Quality Diabetes Education Act of 2013
S. 2689/H.R. 5644 - Medicare CGM Access Act of 2014
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2014
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 17, 2014.
Original Filing: 300659057.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1325/H.R. 1428 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
S. 945/H.R. 1274 - Access to Quality Diabetes Education Act of 2013
H.R. 3710 - Medicare CGM Coverage Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 4800 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015
S. 2389 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
2nd Quarter, 2014
JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) amended a lobbying report for in-house lobbying in Q22014 on July 17, 2014
Original Filing: 300659107.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1325/H.R. 1428 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
S. 945/H.R. 1274 - Access to Quality Diabetes Education Act of 2013
H.R. 3710 - Medicare CGM Coverage Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 4800 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015
S. 2389 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2014
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 17, 2014.
Original Filing: 300639091.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1325/H.R. 1428 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
S. 945/H.R. 1274 - Access to Quality Diabetes Education Act of 2013
S. 1871/H.R. 2810 - SGR Repeal and Medicare Beneficiary Access Act of 2013 H.R. 1724 - Kids First Research Act of 2013
H.R. 2019 - Gabriella Miller Kids First Research Act
S. 2000/H.R. 4015 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014
S. 2110 - Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014
S. 2122 - Responsible Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014
S. 2157 - Commonsense Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014
H.R. 4302 - Protecting Access to Medicare Act of 2014
H.R. 3710 - Medicare CGM Coverage Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1284 Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2014
H.R. 2410 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014
S. 1244 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014H.R. 3547 Consolidated Appropriations Act, 2014
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
4th Quarter, 2013
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 17, 2014.
Original Filing: 300619489.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1325/H.R. 1428 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
S. 945/H.R. 1274 - Access to Quality Diabetes Education Act of 2013
S. 1871 SGR Repeal and Medicare Beneficiary Access Act of 2013 H.R. 1724 Kids First Research Act of 2013
H.R. 2019 Gabriella Miller Kids First Research Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1284 Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2014
H.R. 2410 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014
S. 1244 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014H.R. 2775 Continuing Appropriations Act, 2014
H.J. Res. 59 Continuing Appropriations Resolution, 2014
H.J. Res. 73 National Institutes of Health Continuing Appropriations Resolution, 2014
H.J. Res. 77 Food and Drug Administration Continuing Appropriations Resolution, 2014
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
3rd Quarter, 2013
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 10, 2013.
Original Filing: 300592190.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1325/H.R. 1428 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
S. 945/H.R. 1274 - Access to Quality Diabetes Education Act of 2013
H.R. 1724 Kids First Research Act of 2013
H.R. 2019 To eliminate taxpayer financing of presidential campaigns and party conventions and reprogram savings to provide for a 10-year pediatric research initiative through the Common Fund administered by the National Institutes of Health, and for other purposes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 1284 Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2014
H.R. 2410 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014
S. 1244 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
2nd Quarter, 2013
JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) amended a lobbying report for in-house lobbying in Q22013 on July 19, 2013
Original Filing: 300578682.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1325 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
H.R. 1274 - Access to Quality Diabetes Education Act of 2013
H.R. 1724 Kids First Research Act of 2013
H.R. 2019 To eliminate taxpayer financing of presidential campaigns and party conventions and reprogram savings to provide for a 10-year pediatric research initiative through the Common Fund administered by the National Institutes of Health, and for other purposes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.J. Res. 117 - Continuing Appropriations Act
S. 1284 Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2014
H.R. 2410 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014
S. 1244 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
2nd Quarter, 2013
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 18, 2013.
Original Filing: 300575166.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1325 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
H.R. 1274 - Access to Quality Diabetes Education Act of 2013
H.R. 1724 Kids First Research Act of 2013
H.R. 2019 To eliminate taxpayer financing of presidential campaigns and party conventions and reprogram savings to provide for a 10-year pediatric research initiative through the Common Fund administered by the National Institutes of Health, and for other purposes.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.J. Res. 117 - Continuing Appropriations Act
S. 1284 Department of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2014
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
1st Quarter, 2013
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 19, 2013.
Original Filing: 300557334.xml
Lobbying Issues
H.R.1074/S.539 - National Diabetes Clinical Care Commission Act
S.323/H.R. 1325 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2013
H.R. 1274 - Access to Quality Diabetes Education Act of 2013
H.R. 6309 (112th Congress) - To amend the Public Health Service Act to reauthorize the special diabetes programs for Type I diabetes and Indians under that Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 8 (112th Congress) - American Taxpayer Relief Act of 2012 (112th Congress, but voted on 1/1/13)
H.J. Res. 117 - Continuing Appropriations Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
4th Quarter, 2012
JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) amended a lobbying report for in-house lobbying in Q42012 on Feb. 4, 2014
Original Filing: 300629926.xml
Lobbying Issues
H.R. 1862, Regenerative Medicine Promotion Act of 2011
H.R. 2787/S. 1468, Medicare Diabetes Self-Management Training Act
H.R. 2969/S. 1454 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
H.R. 2960/S. 3430 National Diabetes Clinical Care Commission Act H.R. 6309, To amend the Public Health Service Act to reauthorize the special diabetes programs for Type I diabetes and Indians under that Act.
H.R. 3150/S. 725 Medicare Safe Needle Disposal Coverage Act of 2011
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 8, American Taxpayer Relief Act of 2012
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
4th Quarter, 2012
In Q4, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Jan. 22, 2013.
Original Filing: 300537832.xml
Lobbying Issues
H.R. 1862, Regenerative Medicine Promotion Act of 2011
H.R. 2787/S. 1468, Medicare Diabetes Self-Management Training Act
H.R. 2969/S. 1454 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
H.R. 2960/S. 3430 National Diabetes Clinical Care Commission Act H.R. 6309, To amend the Public Health Service Act to reauthorize the special diabetes programs for Type I diabetes and Indians under that Act.
H.R. 3150/S. 725 Medicare Safe Needle Disposal Coverage Act of 2011
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 8, American Taxpayer Relief Act of 2012
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
3rd Quarter, 2012
In Q3, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on Oct. 22, 2012.
Original Filing: 300518246.xml
Lobbying Issues
H.R. 1862, Regenerative Medicine Promotion Act of 2011
H.R. 2787/S. 1468, Medicare Diabetes Self-Management Training Act
S. 2236, Advancing Breakthrough Therapies for Patients Act
H.R. 2969/S. 1454 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011H.R. 5651, Food and Drug Administration Reform Act of 2012
S. 3187 Food and Drug Administration Safety & Innovation Act
H.R. 6309, To amend the Public Health Service Act to reauthorize the special diabetes programs for Type I diabetes and Indians under that Act.
H.R. 2960/S. 3430 National Diabetes Clinical Care Commission Act
H.R. 3150/S. 725 Medicare Safe Needle Disposal Coverage Act of 2011
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013
H.R.5973, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
H.J. Res. 117, Continuing Appropriations Resolution, 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
2nd Quarter, 2012
In Q2, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on July 19, 2012.
Original Filing: 300492608.xml
Lobbying Issues
H.R. 1862, Regenerative Medicine Promotion Act of 2011
H.R. 2787/S. 1468, Medicare Diabetes Self-Management Training Act
H.R. 2960, National Diabetes Clinical Care Commission Act
S. 2236, Advancing Breakthrough Therapies for Patients ActH.R. 2969/S. 1454 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
H.R. 5651, Food and Drug Administration Reform Act of 2012
S. 3187 Food and Drug Administration Safety & Innovation Act
S. 725, Medicare Safe Needle Disposal Coverage Act of 2011
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013
H.R.5973, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
1st Quarter, 2012
In Q1, JDRF Intl. (formerly known as Juvenile Diabetes Research Foundation Intl.) had in-house lobbyists. The report was filed on April 20, 2012.
Original Filing: 300472977.xml
Lobbying Issues
H.R. 1862, Regenerative Medicine Promotion Act of 2011
H.R. 2787/S. 1468, Medicare Diabetes Self-Management Training Act
H.R. 2960, National Diabetes Clinical Care Commission Act
S. 2236, Advancing Breakthrough Therapies for Patients ActH.R. 2969/S. 1454 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2013
Labor/HHS/Education Appropriations bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
4th Quarter, 2011
In Q4, Juvenile Diabetes Research Foundation Intl. had in-house lobbyists. The report was filed on Jan. 18, 2012.
Original Filing: 300441699.xml
Lobbying Issues
H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012 (Minibus)
H.R. 2055/H.R. 3671, Consolidated Appropriations Act, 2012
H.R. 3070/S. 1599, Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1862, Regenerative Medicine Promotion Act of 2011
H.R. 2787/S. 1468, Medicare Diabetes Self-Management Training Act
H.R. 2376, Stem Cell Research Advancement Act of 2011
H.R. 2960, National Diabetes Clinical Care Commission ActH.R. 2969/S. 1454, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, Juvenile Diabetes Research Foundation Intl. had in-house lobbyists. The report was filed on Oct. 20, 2011.
Original Filing: 300422530.xml
Lobbying Issues
H.R. 2376 Stem Cell Research Advancement Act of 2011
H.R. 1862 Regenerative Medicine Promotion Act of 2011
H.R. 2969/S.1454 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 2112 FY12 Dept of Agriculture Appropriations
Draft House Text/S. 1599 FY12 Labor, HHS, Education, and Related Agencies Appropriations Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on July 20, 2011.
Original Filing: 300403623.xml
Lobbying Issues
H.R. 2376 Stem Cell Research Advancement Act of 2011
H.R. 1862 Regenerative Medicine Promotion Act of 2011
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 2112 FY12 Dept of Agriculture Appropriations
H.R. ___/S. ___ FY 12 Labor, HHS, Education, and Related Agencies Appropriations Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on April 20, 2011.
Original Filing: 300376807.xml
Lobbying Issues
H.R. 4808, Stem Cell Research Advancement Act of 2009
S.3766, Stem Cell Research Advancement Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R._/S.3686, FY 11 Department of Labor, HHS, Education and Related Agencies Appropriations
H.R._/S.3800, FY 11 Department of Defense Appropriations
H.R._/S.3606, FY 11 Department of Agriculture Appropriations (FDA)
H.R._1473, FY 11 Department of Defense Appropriations and Full Year Continuing Appropriations Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on Jan. 20, 2011.
Original Filing: 300350228.xml
Lobbying Issues
H.R. 3668/ S. 3058, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and The Special Diabetes Program for Indians
H.R. 4808, Stem Cell Research Advancement Act of 2009
S.3766, Stem Cell Research Advancement Act of 2010H.R. 4994, Medicare and Medicaid Extenders Act of 2010
H.R. 4853, Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R._/S.3686, FY 11 Department of Labor, HHS, Education and Related Agencies Appropriations
H.R._/S.3800, FY 11 Department of Defense Appropriations
H.R._/S.3606, FY 11 Department of Agriculture Appropriations (FDA)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on Oct. 20, 2010.
Original Filing: 300325072.xml
Lobbying Issues
H.R. 3668/S.3058, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Reserach and The Special Diabetes Program for Indians
H.R. 4808, Stem Cell Research Advancement Act of 2009
S.3766, Stem Cell Research Advancment Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R._/S.3686, FY 11 Department of Labor, HHS, Education and Related Agencies Appropriations
H.R._/S.3800, FY 11 Department of Defense Appropriations
H.R._/S.3606, FY 11 Department of Agriculture Appropriations (FDA)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on July 19, 2010.
Original Filing: 300293386.xml
Lobbying Issues
H.R.___/ S.____, FY 11 Department of Labor, HHS, Education and Related Agencies Appropriations
H.R____/S.____, FY 11 Department of Defense Appropriations
H.R.____/S. 3606, FY 11 Department of Agriculture Appropriations (FDA)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3668/ S. 3058, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and The Special Diabetes Program for Indians
H.R. 873/S.487, Stem Cell Reserach Enhancement Act of 2009
H.R. 872, Stem Cell Reserach Improvement Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
1st Quarter, 2010
In Q1, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on April 20, 2010.
Original Filing: 300267973.xml
Lobbying Issues
H.R. ___, FY 11 Department of Labor, HHS, Education and Related Agencies Appropriations
H.R. ___, FY 11 Department of Defense Appropriations
H.R. ___, FY 11 Department of Agriculture Appropriations (FDA)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3668/ S. 3058, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and The Special Diabetes Program for Indians
H.R. 3200/S.1796, America's Healthy Future Act of 2009
H.R. 3590, The Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on Jan. 20, 2010.
Original Filing: 300241569.xml
Lobbying Issues
H.R. 3293, Department of Labor, HHS, Education and Related Agencies Appropriations
H.R. 3326, Department of Defense Appropriations
H.R. 2997, Department of Agriculture Appropriations (FDA)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3668/S._, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and The Special Diabetes Program for Indians
H.R. 3200/S. 1796, America's Healthy Future Act of 2009
H.R. 3590, The Patient Protection and Affordable Care Act H.R. 873/S.487, Stem Cell Research Enhancement Act of 2009
H.R. 872, Stem Cell Reasearch Improvement Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL filed a lobbying registration on Oct. 6, 2009 for in-house lobbying efforts, effective Oct. 7, 2009.
Original Filing: 300201597.xml
Issue(s) they said they’d lobby about: Dept. of Labor, HHS, Education and Related Agencies Approps; DoD Approps.; Dept. of Agriculture Appropriations.; H.R. 2920, H.R.873/S.487, Stem Cell Research Enhancement Act of 2009; H.R. 872, Stem Cell Research Improvement Act of 2009; H.R._/S._, National Diabetes Coordinator Act; H.R.3668/S._; Reauthorization of the Special Statutory Funding Prog. for Type 1 Diabetes Research and Special Diabetes Program for Indians; Health Care Reform Legislation .
3rd Quarter, 2009
In Q3, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on Oct. 20, 2009.
Original Filing: 300216352.xml
Lobbying Issues
H.R. 3293, Department of Labor, HHS, Educations and Related Agencies Appropriations
H.R. 3326, S._, Department of Defense Appropriations
H.R. 2997, Department of Agriculture Appropriations (FDA)
H.R. 2920, To reinstitute and update the Pay-As-You-Go requirement of budget neutrality on new tax and mandatory spending legislation, enforced by the threat of annual, automatic sequestration.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 3668/S._, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and The Special Diabetes Program for Indians
H.R. 873/ S. 487, Stem Cell Research Enhancement Act of 2009
H.R. 872, Stem Cell Research Improvement Act of 2009 H.R._/S._, National Diabetes Coordinator Act
H.R. 3200, S._, Health care Reform
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on July 20, 2009.
Original Filing: 300187924.xml
Lobbying Issues
H.R._/S._, Department of Labor, HHS, Education and Related Agencies Appropriations
H.R. _, Department of Defense Appropriations
H.R. 2997, Department of Agriculture Appropriations
H.R. 2920, Reinstitute and update the Pay-As-You-Go requirement of budget neutrality on new tax and mandatory spending legislation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 873/S.487, Stem Cell Research Enhancement Act of 2009
H.R. 872, Stem Cell Research Improvement Act of 2009
H.R._/S._, National Diabetes Coordinator Act
H.R._/S._, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and the Special Diabetes Program for Indians
Health Care Reform Legislation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL amended a lobbying report for in-house lobbying in Q12009 on June 7, 2010
Original Filing: 300279842.xml
Lobbying Issues
H.R._/S_, Department of Labor, HHS, Education and Related Agencies Appropriations
H.R._, Department of Defense Appropriations
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense - Dept of (DOD)
Lobbying Issues
H.R. 873 / S.487, Stem Cell Research Enhancement Act
H.R. 877, Patients First Act of 2009
H.R. __/ S.__, National Diabetes Coordinator Act
Health Care Reform Legislation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1, The American Recovery and Reinvestment Act: Title VIII, Departments of Labor, Health and Human Services, and Education, and Related Agencies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
1st Quarter, 2009
In Q1, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on April 17, 2009.
Original Filing: 300155018.xml
Lobbying Issues
H.R._/S_, Department of Labor, HHS, Education and Related Agencies Appropriations
H.R._, Department of Defense Appropriations
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense - Dept of (DOD)
Lobbying Issues
H.R. 873 / S.487, Stem Cell Research Enhancement Act
H.R. 877, Patients First Act of 2009
H.R. __/ S.__, National Diabetes Coordinator Act
Health Care Reform Legislation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R.1, The American Recovery and Reinvestment Act: Title VIII, Departments of Labor, Health and Human Services, and Education, and Related Agencies
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Economics/Economic Development
4th Quarter, 2008
In Q4, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on Jan. 21, 2009.
Original Filing: 300129362.xml
Lobbying Issues
H.R.3043/S.1710, Department of Labor, HHS, Education and Related Agencies Appropriations
H.R. 3222, Department of Defense Appropriations
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense - Dept of (DOD)
Lobbying Issues
H.R. 2762/S.1494, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and the Special Diabetes Program for Indians
H.R. 7141, Stem Cell Research Enhancement Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on Oct. 17, 2008.
Original Filing: 300099218.xml
Lobbying Issues
H.R. 3043/S.1710 Department of Labor, HHS, Education and Related Agencies Appropriations
H.R. 3222 Department of Defense Appropriations
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense - Dept of (DOD) Health & Human Services - Dept of (HHS)
Lobbying Issues
H.R. 2762/ S. 1494, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and the Special Diabetes Program for Indians
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008
H.R. 7141, Stem Cell Research Enhancement Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
P.L. 108-173 Sec. 733. Payment for Pancreatic Islet Cell Investigational Transplants for Medicare Beneficiaries in Clinical Trials
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
2nd Quarter, 2008
In Q2, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on July 21, 2008.
Original Filing: 300077637.xml
Lobbying Issues
H.R. 3043/S.1710 Department of Labor, HHS, Education and Related Agencies Appropriations
H.R. 3222 Department of Defense Appropriations
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense - Dept of (DOD) Health & Human Services - Dept of (HHS)
Lobbying Issues
H.R.2762/S.1494, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and the Special Diabetes Program for Indians
H.R.4836, National Diabetes Coordinator Act of 2008
H.R. 493/S.358, Genetic Information Nondiscrimination Act of 2007H.R.6331/S.3101/S.3118, Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Natl Institutes of Health (NIH)
Lobbying Issues
Discuss emerging technoglogiesfor diabetes management
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
1st Quarter, 2008
In Q1, JUVENILE DIABETES RESEARCH FOUNDATION INTERNATIONAL had in-house lobbyists. The report was filed on April 21, 2008.
Original Filing: 300054325.xml
Lobbying Issues
H.R. ____/S.____ Department of Labor, HHS, Education and Related Agencies Appropriations
H.R. _____Department of Defense Appropriations
Agencies Lobbied
U.S. House of Representatives U.S. Senate Defense - Dept of (DOD) Health & Human Services - Dept of (HHS)
Lobbying Issues
H.R.2762/S.1494, Reauthorization of the Special Statutory Funding Program for Type 1 Diabetes Research and the Special Diabetes Program for Indians
H.R.4836, National Diabetes Coordinator Act of 2008
H.R. 493/S.358, Genetic Information Nondiscrimination Act of 2007
Agencies Lobbied
U.S. House of Representatives U.S. Senate Natl Institutes of Health (NIH) Health & Human Services - Dept of (HHS),
Lobbying Issues
Discuss emerging technologies for diabetes management
Agencies Lobbied
Centers For Medicare and Medicaid Services (CMS) Food & Drug Administration (FDA) Health & Human Services - Dept of (HHS)
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate